Trading

Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients

Summary

Alpha Tau Medical shared positive interim results from a United States clinical trial evaluating Alpha DaRT therapy for recurrent glioblastoma. Data from the ongoing study show complete tumor clearance in all six evaluable patients who reached the MRI response assessment stage.

Alpha Tau Medical Ltd. (NASDAQ:DRTS) on Sunday reported positive interim results from its U.S. REGAIN trial evaluating Alpha DaRT therapy in patients with recurrent glioblastoma.The data capture patient outcomes through November 11, 2026.Strong Tumor Response RatesClinicians have treated eight patients in the trial so far, and six have reached MRI response assessment. Under RANO criteria, all six evaluable patients achieved…

Source: Read the full story at Top Stories Feed

Follow Tech & Money Press for daily watchlists and market news

XFacebookInstagramTikTok
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.
About UsContactPrivacy PolicyDisclaimer
Not financial advice. Curated headlines link to their original publishers.